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Prostaglandins (PGs) belong to the group of 
short-lived lipid signaling compounds that are 
formed from arachidonic acid (AA), after its 
mobilization from membrane phospho lipids 
by any of a broad array of stimuli (Smith et al. 
2000). The molecules act locally in a paracrine 
or autocrine fashion and are involved in such 
processes as early male sexual development 
and masculinization, development of sexual 
behavior, induction of labor, inflammatory 
responses, pain, calcium movement, vaso-
dilation, and hormone regula tion (Adams and 
McLaren 2002; Amateau and McCarthy 2004; 
Gupta 1989; Gupta and Goldman 1986; 
Smith et al. 2000). Deregulation of the PG 
pathway has also been implicated in the patho-
physiology of several diseases, such as cancer 
and cardiovascular and inflammatory diseases 
(FitzGerald 2003). In addition, prenatal inhi-
bition of the pathway with acetaminophen/
paracetamol (Ace), which belongs to the group 
of mild analgesics that are pharma ceuti cal 
cyclo oxygenase (COX) enzyme inhibitors, has 
recently been associated with atopic diseases in 
childhood (Perzanowski et al. 2010; Rebordosa 
et al. 2008; Shaheen et al. 2002, 2005).
We recently noticed that phthalates, 
known endocrine-disrupting compounds 
(EDCs), share a high degree of structural simi-
larity with salicylates such as aspirin [acetyl sali-
cylate (ASA)] that inhibit the COX-mediated 
conversion of AA to PGs, and previous studies 
have indicated that certain phthalates could 
interfere with the pathway (Tavares and Vine 
1985). In the present study, we investigated 
whether known EDCs could interfere with the 
PG pathway in a juvenile mouse Sertoli cell 
line, gestational day (GD) 14.5 fetal rat testes, 
and in primary human mast cells.
Materials and Methods
Cell culture and PG screen assay. SC5 mouse 
juvenile Sertoli cells (Hofmann et al. 1992) 
were cultured in Dulbecco’s modified Eagle’s 
medium with 10% fetal calf serum (FCS), 
100 U/mL penicillin, 100 µg/mL strep-
tomycin, and 1 mM l-glutamine (all from 
Invitrogen, San Diego, CA, USA) at 37°C 
with 5% CO2. Only phthalate-free poly-
styrene flasks and 12-well plates (NUNC, 
Roskilde, Denmark) were used. The day before 
each experiment, 105 SC5 cells were seeded in 
each well in a 12-well plate. The next day, 
media were removed and 1 mL fresh medium 
containing either a test compound or vehicle 
was added. Peroxisome proliferator–activated 
receptor-α (PPARα) and retinoid X recep-
tor (RXR) agonists (613333 and LGD1069, 
respectively) were kindly provided by 
P. Sauerberg (Novo Nordisk, Bagsværd, 
Denmark); all other receptor ligands and 
EDCs (listed in Table 1) were purchased 
from Sigma-Aldrich (St. Louis, MO, USA) or 
Cayman Chemicals (Ann Arbor, MI, USA). 
The compounds were tested in at least three 
concentrations with the far left row in the 
plate containing the highest concentration 
and with decreasing concentrations toward 
the right side of the plate. Negative controls 
were always in the far right next to the lowest 
concentration of test compound. Twenty-four 
hours after exposure, media were removed and 
snap frozen on dry ice for later PG measure-
ments, and cells were either harvested for 
RNA or used for cytotoxicity tests. To mini-
mize the number of cells lost during medium 
changes, all pipetting was carried out with 
media added in droplets, and care was taken 
to minimize contact of the pipette tip with the 
bottom of the well.
Culture and differentiation of primary 
human mast cells. Primary human mast cells 
were generated from CD133+ cells from buffy 
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Background: Prostaglandins (PGs) play key roles in development and maintenance of homeostasis 
of the adult body. Despite these important roles, it remains unclear whether the PG pathway is a 
target for endocrine disruption. However, several known endocrine-disrupting compounds (EDCs) 
share a high degree of structural similarity with mild analgesics.
oBjectives and Methods: Using cell-based transfection and transduction experiments, mass 
spectrometry, and organotypic assays together with molecular modeling, we investigated whether 
inhibition of the PG pathway by known EDCs could be a novel point of endocrine disruption.
results: We found that many known EDCs inhibit the PG pathway in a mouse Sertoli cell line 
and in human primary mast cells. The EDCs also reduced PG synthesis in ex vivo rat testis, and this 
reduction was correlated with a reduced testosterone production. The inhibition of PG synthesis 
occurred without involvement of canonical PG receptors or the peroxisome proliferator–activated 
receptors (PPARs), which have previously been described as targets of EDCs. Instead, our results 
suggest that the compounds may bind directly into the active site of the cyclooxygenase (COX) 
enzymes, thereby obstructing the conversion of arachidonic acid to PG precursors without inter-
fering with the expression of the COX enzymes. A common feature of the PG inhibitory EDCs 
is the presence of aromatic groups that may stabilize binding in the hydrophobic active site of the 
COX enzymes.
conclusion: Our findings suggest a hitherto unknown mode of action by EDCs through inhibi-
tion of the PG pathway and suggest new avenues to investigate effects of EDCs on reproductive and 
immunological disorders that have become increasingly common in recent decades.
key words: antiandrogens, benzophenones, cyclooxygenase, endocrine disruptors, parabens, 
phthalates, PPARs, prostaglandins. Environ Health Perspect 119:534–541 (2011). doi:10.1289/
ehp.1002635 [Online 16 November 2010]
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coat preparations as described previously 
(Holm et al. 2008). In brief, CD133+ cells 
were separated using the AC133 cell isolation 
kit and a magnetic LS+ separation column 
according to the manufacturer’s instruc-
tions (Miltenyi Biotech, Bergisch Gladbach, 
Germany). The purified CD133+ cells were 
suspended at 5 × 105 cells/mL in StemSpan 
medium (Stem Cell Technologies, Vancouver, 
British Columbia, Canada) supplemented 
with 100 ng/mL human recombinant stem 
cell factor (rhSCF; R&D Systems, Abingdon, 
UK), 50 ng/mL human recombinant inter-
leukin-6 (rhIL-6; R&D Systems), 1 ng/mL 
human recombinant interleukin-3 (rhIL-3; 
PeproTech, London, UK), and 100 µg/mL 
penicillin/streptomycin (GIBCO BRL, Grand 
Island, NY, USA) and grown for 3 weeks, 
after which rhIL-3 was omitted from the cul-
ture media. From week 6, 10% FCS (GIBCO 
BRL) was added, and mast cells were analyzed 
after 1 week. Cells were cultured in suspen-
sion for the entire period, and medium was 
renewed weekly.
Mature mast cells were sensitized by 
 incuba tion with 2 µg/mL human myeloma 
IgE, kindly provided by L.K. Poulsen 
(National University Hospital, Copenhagen, 
Denmark) for 24 hr at 37°C in StemSpan 
medium (Stem Cell Technologies) supplied 
with 100 ng/mL rhSCF and 50 ng/mL rhIL-6. 
The sensitized mast cells were washed, and 
104 cells were resuspended in 100 µL PIPES 
[piperazine-N,N´-bis(2-ethanesulfonic acid)] 
buffer with rhSCF and rhIL-6. Cells were 
activated by incubation with 100 µL anti-IgE 
(5 µg/mL; Dako, Glostrup, Denmark) for 
30 min at 37°C. 
Animals and culture of GD14.5 testes. 
Animal experiments were approved by the 
local ethics committee, and the animals 
were treated humanely with regard for alle-
viation of suffering. Pregnant female Sprague-
Dawley rats bred in-house (Groupe d’Etude 
de la Reproduction Chez l’Homme et les 
Mammiferes–INSERM U625; Rennes, 
France) were anesthetized by intra peritoneal 
injection with 40 mg/kg sodium pento-
barbital (Sanofi-Synthélabo, Libourne, 
France) on GD14.5. The testes were asep-
tically removed from male fetuses under a 
binocular microscope and then immediately 
explanted in vitro.
Testes were cultured on Millipore fil-
ters (0.45 µm pore size; Millipore Corp., 
Bedford, MA, USA), as previously described 
(Chauvigne et al. 2009; Habert et al. 1991; 
Lassurguere et al. 2003). Briefly, each 
GD14.5 fetal testis was removed with the 
adjacent mesonephros, placed on a filter 
floating in a culture dish on 0.5 mL M199 
medium (Invitrogen) supplemented with 
50 µg/mL gentamicin (Life Technologies, 
Cergy-Pontoise, France) and 2.5 µg/mL 
fungi zone (Life Technologies), and incu-
bated in a humidified atmosphere (5% CO2 
at 37°C) for 24, 48, or 72 hr. Two testes were 
cultured in 500 µL medium containing either 
vehicle [dimethyl sulfoxide (DMSO)] or a test 
compound. Half of the volume of the culture 
medium was refreshed every 24 hr.
Electroporation. SC5 cells (8 × 105) were 
electroporated using Amaxa Nucleofector 
(Lonza, Basel, Switzerland) in 100 µL 
electro poration buffer [20 mM HEPES, 
pH 7.0; 137 mM NaCl; 5 mM KCl; 
0.7 mM Na2HPO4; 6 mM glucose; 0.1 mM 
β-mercaptoethanol) containing 10 µM or 
100 µM mono-n-butyl phthalate (MBP), 
10 µM di-n-butyl phthalate (DBP), or etha-
nol vehicle. Immediately after electro poration, 
cells were transferred to media without phtha-
late and cultured in 12-well plates. Cells were 
cultured 6 hr before media were harvested for 
prostaglandin D2 (PGD2) measure ment.
Cytotoxicity assay. After phthalate expo-
sure, cells were counted and the cell number 
was compared with controls. We tested cyto-
toxicity of the phthalates after 24 hr exposure 
using a TOX-8 In Vitro Toxicology Assay Kit 
(Sigma Aldrich, St. Louis, MO, USA). 
Testosterone and PG measure ment. Half 
the medium of each testis culture was recov-
ered every 24 hr and stored at –80°C until 
analysis by testosterone radioimmunoassay 
using a Coat-A-Count Total Testosterone Kit 
(Siemens, Los Angeles, CA, USA) without 
prior extraction. PGD2 and prostaglandin E2 
(PGE2) were determined by Prostaglandin 
D2-MOX enzyme immuno assay (EIA) and 
Prostaglandin E2 EIA Kit–Monoclonal 
(Cayman Chemicals), respectively. The plates 
Table 1. IC50 values for inhibition of PG secretion from mouse SC5 cells.
Test compound Abbreviation IC50
Pharmaceutical inhibitors
Acetyl salicylate (aspirin) ASA 1.64 × 10–6 
Acetaminophen/paracetamol Ace 3.82 × 10–7 
Ibuprofen Ibu 1.12 × 10–8 
Indomethacin Indo 4.24 × 10–7 
Phthalates
Dimethyl phthalate DMP No effect
Diethyl phthalate DEP 1.9 × 10–5 
Di-n-propyl phthalate DPP 2.1 × 10–6 
Di-n-butyl phthalate DBP 2.11 × 10–6 
Diisobutyl phthalate DiBP 1.01 × 10–6 
Butylbenzyl phthalate BBzP 2.45 × 10–5 
Di-n-pentyl phthalate DPeP 1.49 × 10–4 
Di-n-benzyl phthalate DBzP 4.17 × 10–4 
Di-n-nonyl phthalate DNP No effect
Diisononyl phthalate DiNP No effect
Di-2-ethylhexyl phthalate DEHP No effect
Parabens
Ethylparaben EPa 7.59 × 10–6 
n-Propylparaben PPa 2.85 × 10–6 
n-Butylparaben BPa 2.43 × 10–6 
Isobutylparaben iBPa 1.09 × 10–6 
n-Pentylparaben PePa 4.83 × 10–7 
Benzylparaben BzPa 1.30 × 10–6 
n-Nonylparaben NPa 2.91 × 10–6
Benzophenones
Benzophenone 3 BP3 1.97 × 10–7 
Benzophenone 7 1.20 × 10–6 
Benzophenone 4 4.56 × 10–5 
Benzophenone 12 6.94 × 10–5 
Estrogen and estrogenic compounds
17β-Estradiol 11.28 × 10–2 
Diethylstilbestrol DES 2.72 × 10–5 
Zearalenol 3.18 × 10–6 
Genistein 4.28 × 10–4 
Bisphenol A BPA 2.72 × 10–6 
Coumestrol 1.25 × 10–5 
Nonylphenol No effect
Antiestrogenic compounds
Tamoxifen Increase at 10 µM
4-OH tamoxifen Increase at 10 µM
ICI 182780 ICI No effect
Androgens and antiandrogen
Testosterone Increase at 10 µM
Dihydrotestosterone Increase at 10 µM
Flutamide 1.87 × 10–6 
IC50, half-maximal inhibitory concentration. 
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were read at 405 nM with a reference wave-
length of 620 nM.
Real-time polymerase chain reaction 
(PCR) analysis. We isolated RNA using the 
NucleoSpin RNA II purification kit with 
DNase I treatment as described by the manu-
facturer (Macherey-Nagel, Düren, Germany). 
One microgram of DNase I–treated RNA 
was reverse transcribed with avian myelo-
blastosis virus reverse transcriptase (USB 
Corp., Cleveland, OH, USA) using dT20 
primers and random hexamers, and was ulti-
mately resuspended in 100 µL Tris-EDTA 
buffer. Quantitative reverse transcriptase PCR 
(RT-PCR) analy sis was performed in triplicate 
in a Stratagene Mx3000P system (Stratagene, 
La Jolla, CA, USA) with Brilliant SYBR 
Green QPCR Master Mix (Stratagene), using 
35 cycles for amplification. PCR products 
were run on 2% agarose gels and visualized by 
ethidium bromide staining. Representative 
bands from each primer combination were 
excised and sequenced for verification (Eurofins 
MWG Operon, Ebersberg, Germany). 
Primers [see Supplemental Material, Table 1 
(doi:10.1289/ehp.1002635)] were obtained 
from DNA Technology (Aarhus, Denmark).
PPAR reporter and PPAR trans activation 
experiments and viral transduction. We per-
formed PPAR response element reporter 
(TK-PPRE-luc) and PPAR trans activation 
(PPARδ-LBD/Gal4, PPARγ-LBD/Gal4, pM, 
and UAS-luc) experiments as described previ-
ously (Christensen et al. 2009; Hansen et al. 
2001). SC5 cells (104) were transfected using 
FuGENE HD (Roche, Basel, Switzerland) 
in 96-well plates with the plasmids and 
cytomegalo virus–Renilla. The experiments were 
initiated 24 hr after transfection, and cells were 
harvested 48 hr after transfection. Harvested 
cells were assayed for luciferase activity using 
Promega Dual-Luciferase Reporter Assay 
(Promega, Madison, WI, USA). Viral experi-
ments were performed as described by Hansen 
et al. (2001) and Nielsen et al. (2008).
Figure 1. COX-2 enzyme expression and PGD2 secretion in the SC5 juvenile mouse Sertoli cell line. (A) Membrane-bound COX-2 enzyme located in the endoplas-
mic reticulum and nuclear envelope (weak 4´,6-diamidino-2-phenylindole (DAPI) nuclear counterstaining); bar = 50 µm. Inhibition of PGD2 secretion from mouse 
SC5 cells by ASA (B), Ace (C), Ibu (D), and Indo (E), normalized (norm) to control values. Data are mean ± SE for three experiments performed in triplicate. 
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Figure 2. Endocrine disruptors inhibit PG synthesis in the SC5 juvenile mouse Sertoli cell line. DBP (A), BPa (B), BP3 (C), and BPA (D) dose-dependently inhibit 
secretion of PGD2 after incubation for 24 hr [normalized (norm) to control values]. (E) Incubation for 24 hr with MBP and MEHP, monoesters of DBP and DEHP, 
showed that they had no inhibitory effect on PGD2 secretion from SC5 cells. (F) LC-MS/MS analysis for MBP and MEHP after exposure to parental compounds 
DBP and DEHP and the monoesters revealed that MBP and MEHP were not taken up by SC5 cells. (G) Electroporation with MBP showed that the compound has 
inhibitory effect on PGD2 secretion from SC5 cells. (H) PGE2 is dose-dependently inhibited by DBP, BPa, BP3, and BPA in SC5 cells after 24 hr incubation. Data are 
mean ± SE for three experiments performed in triplicate. 
*p < 0.05, **p < 0.01, and #p < 0.001, compared with controls by two-tailed Student’s t-test.
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Liquid chromatography–tandem mass 
spectrometry (LC-MS/MS). All experiments 
were performed three times in triplicate in 
12-well plates with 105 cells in each well. After 
24 hr, cells were exposed to 10 µM DBP, 
10 µM MBP, 10 µM di-2-ethylhexyl phthalate 
(DEHP), 10 µM mono-2-ethylhexyl phtha-
late (MEHP), or vehicle. In addition, media 
containing phthalates were also incubated in 
12-well plates without cells to test for possible 
contamination. The next day, cells were har-
vested by trypsinization, washed three times 
with phosphate-buffered saline, centrifuged 
to a pellet in an Eppendorf tube, and imme-
diately frozen at –80°C together with samples 
of the media. Methanol (60 µL) was added to 
each tube; pellets were then sonicated at 36°C 
for 15 min and centrifuged. The supernatants 
were immediately transferred to phthalate-free 
glass tubes.
Monoester phthalates (MBP and MEHP) 
were measured as described by Frederiksen 
et al. (2008). The limits of detection (LODs) 
were 0.94 ng/mL and 0.18 ng/mL for MBP 
and MEHP, respectively. Secondary DEHP 
metabo lites [mono-(2-ethyl-5-hydroxyhexyl) 
phthalate (5-OH-MEHP; LOD < 0.60 
ng/mL), mono-(2-ethyl-5-oxohexyl) phthalate 
(5-OXO-MEHP; LOD < 0.14 ng/mL), and 
mono-(2-ethyl-5-carboxypentyl) phthalate 
(5-CX-MEPP; LOD < 0.43 ng/mL)] were 
also measured in SC5 cells, but levels were 
consistently < LODs.
Molecular modeling of chemical binding 
to the COX active site of COX-2. We assessed 
molecular modeling on COX-2 protein by 
standard computer modeling studies using 
MOE 2007.09 (Chemical Computing Group 
Inc., Köln, Germany). We obtained the crystal 
structure of murine COX-2, which is very simi-
lar to human COX-2 (Kurumbail et al. 1996), 
from the Protein Data Bank (accession no. 
1PXX; Research Collaboratory for Structural 
Bioinformatics 2010; Rowlinson et al. 2003). 
Each compound was docked using alpha tri-
angle for the placement phase and London dG 
scoring for the scoring function.
Statistical analysis. All results are presented 
as mean ± SE of all experimental replicates, 
except for quantitative RT-PCR, where results 
are presented as mean ± SD. We assessed sta-
tistical significance using a two-sided unpaired 
Student’s t-test; p < 0.05 indicates statistical 
significance.
Results
EDCs dose-dependently inhibit PG synthe-
sis. Overnight incubation of 105 SC5 cells 
(Figure 1A) in a 12-well plate with 1 mL 
medium resulted in approximately 300 pg/mL 
PGD2 and approximately 15 ng/mL PGE2. 
This secretion was dose-dependently inhibited 
by Ace, ASA, ibuprofen (Ibu), and indometha-
cin (Indo) after 24 hr incubation (Figure 1B–E). 
Similar dose-dependent inhibition of PGD2 
secretion from Sertoli cells was evident after 
incubation with many EDCs, including bis-
phenol A (BPA), genistein, diethyl stil bestrol 
(DES), and flutamide (Figure 2A–D; for an 
extended list, see Table 1). We found no signs 
of cytotoxicity. The most potent inhibition of 
PGs occurred with benzo phenone 3 (BP3), 
diisobutyl phthalate (DiBP), and isobutyl-
paraben (iBPa), which were more potent than 
ASA and Ace. We saw no reduction in secre-
tion of PGs after 24 hr incubation with natural 
estrogen and testosterones. Instead, testoster-
one, dihydro testosterone, and tamoxifen, all at 
10 µM, actually increased PG production. 
Effect of phthalate monoesters. MBP, the 
monoester of DBP, had no inhibitory effect 
on PGD2, nor did MEHP (Figure 2E) or 
DEHP (data not shown). This was puzzling 
because MBP, DEHP, and MEHP are all 
known to have endocrine-disrupting effects 
on male development (Scott et al. 2009). 
LC-MS/MS revealed that DBP and DEHP 
entered the cells, where they were converted 
to monoesters, whereas the monoesters 
MBP and MEHP were excluded probably 
because of their negative charge (Figure 2F). 
Because MBP has been argued to be the active 
metabo lite of DBP, we electroporated 10 µM 
and 100 µM MBP into the SC5 cells, which 
at 100 µM resulted in a significant inhibi-
tion of PGD2 after 6 hr (Figure 2G). Thus, 
these results suggest that DBP passes into the 
cells, where it is metabolized to MBP, which 
(possibly together with DBP) subsequently 
inhibits PG synthesis. LC-MS/MS showed no 
other metabolites of DEHP in the cells except 
MEHP, indicating that the cells had a very 
limited capacity to create secondary metabo-
lites such as 5-OH-MEHP, 5-OXO-MEHP, 
and 5-CX-MEPP (Koch et al. 2005).
To investigate whether MEHP and MBP 
could modulate PGD2 production in fetal 
testes, we incubated GD14.5 rat testes with 
10 µM of either compound. PGD2 secretion 
was reduced after 24 hr for both compounds; 
however, the change was not statistically 
significant for MEHP (Figure 3A,B). After 
Figure 3. Inhibition of PG synthesis in fetal testes from GD14.5 rats (A–E) and SC5 juvenile mouse Sertoli 
cells (F). (A) MBP (10 µM) inhibits secretion of PGD2 after 24 hr culture. (B) MEHP (10 µM) weakly inhibits 
PGD2 secretion after 24 hr. (C) The inhibitory action of MEHP is evident after stimulation of PGD2 syn-
thesis with 100 µM AA for all time points, also implying that the inhibition is downstream from AA. The 
CYP17 inhibitor ketoconazole reduced testosterone production (D) but did not affect PGD2 synthesis (E). 
(F) Stimulation of PGD2 secretion from SC5 cells with 1 and 100 µM AA is inhibited by DBP, BPa, BP3, and 
BPA, normalized (norm) to control values. Similar action is seen with pharmaceutical inhibitors ASA, Ace, 
and Ibu, indicating that DBP, BPa, BP3, and BPA are inhibiting the COX enzymes. Data are mean ± SE for 
three experiments performed in triplicate. 
*p < 0.05, **p < 0.01, and #p < 0.001, compared with controls by two-tailed Student’s t-test.
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PGD2 production was increased by stimula-
tion of the GD14.5 testes with 100 µM AA, 
10 µM MEHP exposure resulted in signifi-
cant inhibition of PGD2 secretion through-
out 72 hr of culture (Figure 3C). The CYP17 
inhibitor ketoconazole (Scott et al. 2009) 
reduced testosterone production without 
affecting PGD2 synthesis (Figure 3D,E).
COX enzymes are the likely point of inhibi-
tion. We used the SC5 cell assay to investigate 
whether PGE2 synthesis also was inhibited by 
DBP, n-butylparaben (BPa), BP3, and BPA 
(Figure 2H). For all, we found dose responses 
similar to those for PGD2, implying that the 
point of inhibition is upstream from PGD2 
and PGE2 synthases in the PG pathway. 
The previous experi ments with GD14.5 rat 
testes showed that AA did not prevent MEHP-
mediated inhibition of PGD2. To verify these 
results, we incubated SC5 cells for 24 hr with 
either Ace, ASA, Ibu, DBP, BPa, BP3, or BPA 
and then stimulated with 1 µM or 100 µM AA 
in medium containing the same compounds 
for 1 hr. The results showed that all com-
pounds had an inhibitory effect (Figure 3F), 
signifying that the point of inhibition most 
likely is COX-1 and COX-2.
The inhibitory effect of the EDCs is not 
mediated through the canonical PGD2 and 
PGE2 receptors. With data suggesting that 
the point of inhibition by the EDCs is the 
COX enzymes, we focused on the mode of 
action. Because DBP has some structural 
resemblance to PGs (Tavares et al. 1984), a 
mechanism through the PG receptors seemed 
plausible. However, exposure to BW245c, 
an agonist for PGD2 receptor (DP1) did not 
affect the synthesis of PGD2, and AH6809, 
an inhibitor of both DP1 and PGE2 recep-
tor (EP1), had no effect on the inhibitory 
effect of DBP on PGD2 secretion from SC5 
cells [see Supplemental Material, Figure 1a,b 
(doi:10.1289/ehp.1002635)], suggesting 
that the PGD2 and PGE2 receptors were 
not involved in the inhibitory action of the 
compounds.
The inhibitory effect of the EDCs is not 
mediated through PPARs. Because phthalates, 
BPA, and other known EDCs are activators 
of PPARs (Diamanti-Kandarakis et al. 2009), 
we investigated whether the inhibitory effect 
was mediated through PPARs. Two differ-
ent PPARδ (also known as PPARβ) agonists 
(GW0742 and GW501516) and a PPARδ 
antagonist (GSK0660) dose-dependently 
inhibited PGD2 secretion from SC5 cells 
[see Supplemental Material, Figure 1c–e 
(doi:10.1289/ehp.1002635)]. Moreover, 
the PPARγ and RXR agonists rosiglitazone 
and LGD1069 (see Supplemental Material, 
Figure 1f and Figure 1i, respectively) had sim-
ilar but weaker effects, whereas two different 
PPARα agonists (613333 and GW590735) 
had no effect (see Supplemental Material, 
Figure 1g,h). Surprisingly, retroviral over-
expression of PPARδ, PPARγ, and PPARα 
in SC5 cells (see Supplemental Material, 
Figure 2a) resulted in no net change in PGD2 
inhibition after incubation with DBP, BPa, 
BP3, or BPA (see Supplemental Material, 
Figure 2b). Lentivirus-mediated short hair-
pin RNA (shRNA) knockdown of PPARδ or 
PPARγ, which effectively reduced the respec-
tive mRNA levels (see Supplemental Material, 
Figure 2c), further indicated no association 
between the inhibitory effect of DBP, BPa, 
BP3, or BPA on PG synthesis and the PPAR 
genes (see Supplemental Material, Figure 2d).
As an independent confirmation of 
these data, we transfected SC5 cells with a 
PPAR-responsive luciferase reporter plasmid 
(TK-PPRE-luc), and the next day we exposed 
the cells to DBP, BP3, BPa, or n-propyl paraben 
(PPa) and PPAR agonists or antagonists for 
24 hr. The results showed no PPAR-activated 
transcription after exposure to DBP and BP3, 
whereas BPa and PPa slightly increased PPAR 
activity [see Supplemental Material, Figure 2e 
(doi:10.1289/ehp.1002635)]. Focusing on 
the mouse ligand-binding domain (LBD) 
of PPARδ and PPARγ, we transfected cells 
with PPARδ-LBD/Gal4 and PPARγ-LBD/
Gal4 expression vectors together with a Gal4-
responsive luciferase reporter plasmid; the next 
day cells were exposed to DBP, DiBP, BP3, 
PPa, or BPa. Again, we observed no increase 
in transcriptional activation (see Supplemental 
Material, Figure 2f,g), confirming that the 
inhibitory activity of the EDCs on PG synthe-
sis is unlikely to be mediated by PPARs.
The inhibitory effect of EDCs is not 
mediated by consistent changes in COX gene 
expression. Many of the compounds identified 
as PG synthesis inhibitors (Table 1) are also 
known to have estrogenic effects (Diamanti-
Kandarakis et al. 2009). However, the lack of 
consistency between the strength of PG inhi-
bition and the known estrogenic potency and 
lack of inhibition by 17β-estradiol and anti-
estrogens (i.e., ICI 182780, tamoxifen, and 
4-hydroxy-tamoxifen) imply that the effect 
is not mediated through estrogen receptors. 
However, to further investigate the possible 
role of expression levels of Cox1 and Cox2 
(Pghs1 and Pghs2) genes in SC5 cells, we per-
formed real-time PCR on RNA (complemen-
tary DNA) from cells exposed to some of the 
compounds that changed PG secretion. We 
observed no significant changes in expres-
sion levels for the two Cox genes, except for 
an increase in expression level after exposure 
to BP3 [see Supplemental Material, Table 2 
(doi:10.1289/ehp.1002635)]. Thus, the inhi-
bition of PG synthesis was not associated with 
decreased expression of the COX genes.
EDCs interfere with PG secretion in 
human immune mast cells. To test whether 
human PG synthesis also was inhibited, we 
focused on the immune system, where PGD2 
secretion from mast cells plays a key role in 
immediate-type hypersensitivity reactions such 
as anaphylactic reaction, acute asthma, and 
allergic rhinitis (Ishizaka et al. 1983). Primary 
in vitro differentiated human mast cells (105) 
were sensitized with human myeloma IgE 
and exposed to test compounds for 24 hr, 
followed by activation of the surface recep-
tor FcεRI with anti-IgE. After 30 min the 
cells had secreted approximately 25 ng/mL 
PGD2 on average. This PGD2 pulse was 
dose-dependently inhibited by Ace, ASA, 
DBP, BPa, BP3, and BPA (Figure 4A).
Modeling suggests that the EDCs directly 
inhibit COX enzymes. Phthalates and parabens 
are structurally similar compounds, and there 
seemed to be a correlation between the length 
of the alkyl side chain of DiBP and iBPa and 
the potency of inhibition (Figure 4B,C and 
Table 1). For example, for both phthalates 
and parabens, compounds with isobutyl side 
chains had the most pronounced inhibitory 
effects, which suggests a similar mode of 
action. Because of the high level of structural 
similarity between phthalates and some com-
mercial COX inhibitors, as exemplified by 
MBP and valeryl salicylate (Figure 4D), we 
conducted simulation of the compounds into 
the binding pocket of COX-2. The binding 
site of COX enzymes is a hydrophobic channel 
with possible hydrogen bonding at the mouth 
with Tyr355 and Arg120 and at the bottom of 
the channel with Tyr385. The ASA acetylation 
site, Ser530, is positioned below Tyr385 and 
is another possible target for hydrogen bond-
ing (Kurumbail et al. 1996; Luong et al. 1996; 
Picot et al. 1994). Modeling showed that 
mean predicted dissociation constant (pre-
dicted pKi) scores of the binding of DBP, BPa, 
BP3, and BPA simulated into the COX-2 
active site were higher than the Andrews mean 
pKi [see Supplemental Material, Table 3a 
(doi:10.1289/ehp.1002635)] that estimates 
docking in a random binding site, implying 
that these compounds could be accommo-
dated in the ligand binding pocket of COX-2.
The simulations also provided an explana-
tion for the observed differences in potencies 
seen for the phthalates and parabens. Placing 
molecules of each paraben from methyl to 
butyl side chains (n = 1–4) within the active 
site of COX-2, in a position allowing the best 
match with hydrogen bonding to Ser530 and 
Tyr385 by the carbonyl groups in the ester 
bonds, showed that differences in the pre-
dicted pKi scores [see Supplemental Material, 
Table 3a (doi:10.1289/ehp. 002635)] were 
similar to the observed differences in half-
maximal inhibitory concentration (IC50) 
(Table 1). We obtained similar results with 
predictions for both phthalate diesters and 
monoesters. Thus, the binding affinity of the 
phthalates and parabens can be explained by 
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hydrophobic and van der Waals inter actions 
in the channel lined with hydrophobic resi-
dues. The strength of the inter actions increases 
with increasing length of the alkyl group and 
with branching, as demon strated by the high 
hydrophobic inter action potential of com-
pounds with an isobutyl side chain (DiBP 
and iBPa). The importance of the hydropho-
bic binding for ligand–COX-2 inter action 
is well documented (Soliva et al. 2003). The 
simulation also suggests that with increasing 
side chain length (n > 5), compounds begin 
to get too large for the binding site, which 
reduces the affinity, possibly explaining the 
decrease in potency of longer chained phtha-
lates such as DEHP, di-n-nonyl phthalate, 
and diisononyl phthalate. Consistent with 
this, the modeling also suggests that for the 
larger phthalates, metabolites are more likely 
candidates for inhibitory action than are 
the parent compounds. Hence, the second-
ary metabo lites of DEHP (5-OH-MEHP, 
5-OXO-MEHP, and 5-CX-MEPP) all had 
higher affinity in the model than did DEHP 
and MEHP, because they may form hydro-
gen bonds both with Arg120 and Tyr355 at 
the mouth of the channel and with Tyr385 
at the bottom [see Supplemental Material, 
Table 3b), supporting the notion that the 
active metabo lite of DEHP is not MEHP but 
one of the secondary compounds that were 
not detected in SC5 cells.
Discussion
In this study we found that many putative 
EDCs inhibit the PG pathway. Using various 
experiments, including viral transduction and 
transfection assays, we observed that PG inhi-
bition is independent of PGD and PGE recep-
tors (DP and EP) and PPAR receptors and 
that it occurs without changes in the expres-
sion of the Cox genes. Instead, our data sug-
gest that the compounds directly interfere with 
the activity of the COX enzymes in a manner 
similar to mild analgesics such as ASA, Ace, 
and Ibu.
Sertoli cells have been hypothesized to 
be a central point of endocrine disruption 
during prenatal development of the testes 
(Skakkebaek et al. 2001), and signaling from 
fetal Sertoli cells is sensitive to PGs. PGD2 
has been shown to be involved in early sexual 
differentiation (Adams and McLaren 2002), 
and other studies have shown that the PG 
pathway in general is important for the mas-
culinization of the male reproductive tract 
(Gupta 1989; Gupta and Bentlejewski 1992; 
Gupta and Goldman 1986). We used the 
SC5 juvenile mouse Sertoli cell line to screen 
for inhibition of PG synthesis because it pro-
duces high amounts of PGs without prior 
 stimulation.
The monoesters MBP and MEHP did 
not enter the SC5 cells as readily as did the 
diesters (DBP and DEHP), possibly because 
the charged molecules cannot pass the plasma 
membrane. Accordingly, we found no effect 
on PGD2 secretion from the cells. However, 
electroporation of MBP into the cells showed 
that MBP does inhibit PGD2 secretion. We 
cannot explain why MBP inhibited the secre-
tion of PGD2 in the fetal rat testes, but we 
speculate that MBP uptake may differ from 
that of SC5 cells. 
Neither DEHP nor its primary metabo-
lite, MEHP, inhibited the secretion PGD2 
from SC5 cells. LC-MS/MS showed that the 
secondary metabolites were not detectable in 
the cells, and modeling suggested that DEHP 
and MEHP did not fit well into the active site 
of the COX-2 enzymes. However, exposing 
GD14.5 fetal rat testes to MEHP reduced 
PGD2 secretion, which became significant 
after stimulation of PG synthesis with AA. We 
therefore speculate that the responsible metab-
olite is not MEHP, but 5-OH-MEHP, the 
first metabolite of MEHP, which has also been 
found to have an anti androgenic effect in fetal 
testis (Chauvigne et al. 2009) but is not detect-
able in SC5 cells.
All the investigated compounds that had 
an inhibitory action on PG synthesis have 
one or more apolar benzene rings, a struc-
tural feature known to play a central role in 
COX inhibition by pharmaceutical inhibitors 
(Soliva et al. 2003). This can be attributed to 
inter actions between the apolar rings and the 
hydrophobic amino acids lining the channel 
of COX enzymes, an inter action predicted to 
stabilize the binding with van der Waals inter-
actions. Supporting this concept, EDCs with-
out aromatic rings, such as perfluoro octanoic 
acid, perfluorosulfonic acid, and citral, showed 
no PG inhibitory effect in SC5 cells (data 
not shown). Furthermore, phenol alone and 
substituted phenols in general inhibit COX 
enzyme activity through binding in the active 
site, thereby obstructing enzyme kinetics 
(Hsuanyu and Dunford 1992), which signi-
fies the inhibitory effect of the benzene group 
on the PG pathway. The best known of these 
substituted phenols is Ace, but others are cate-
chol, cate cholamines (e.g., adrenalin), hydro-
quinone, eugenol (the principal component of 
natural analgesic clove oil), and resveratrol (an 
active component of red wine) (Graham et al. 
Figure 4. Endocrine disruptors share structural features with mild analgesics and inhibit PGD2 secretion 
from primary human mast cells. (A) Secretion of PGD2 from primary human mast cells after stimulation 
with IgE and anti-IgE is dose-dependently inhibited by exposure to DBP, BPa, BP3, BPA, ASA, and Ace 
(n = 8). (B and C) Secretion of PGD2 after exposure to different compounds (at 10 µM), indicating that 
compounds with an isobutyl side chain (DiBP and iBPa) cause the most potent inhibition (n = 3). Data 
are normalized (norm) to control values. (D) Phthalates share structural similarities with salicylates, here 
exemplified with valeryl salicylate and MBP. Data are mean ± SE. Abbreviations: BzPa, benzyl paraben; 
DBzP, dibenzyl phthalate; DEHP, diethylhexyl phthalate; DEP, diethyl phthalate; DiBP, diisobutyl phthalate; 
DiNP, di-isononyl phthalate; DMP, dimethyl phthalate; DNP, di-n-nonyl phthalate; DPeP, di-n-pentyl phtha-
late; DPP, di-n-propyl phthalate; EPa, ethylparaben; HBa, 4-hydroxy benzoic acid; iBPa, isobutylparaben, 
MPa, methylparaben, NPa, n-nonylparaben; PePa, n-pentylparaben; PPa, n-propylparaben. 
*p < 0.05, **p < 0.01, compared with controls by two-tailed Student’s t-test. 
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2001; Zykova et al. 2008). Our data suggest 
that parabens and more complex molecules 
with multiple phenol groups, such as BP3, 
BPA, DES, and genistein, should be added to 
the already characterized substituted phenols 
with inhibitory effects on PG synthesis.
Tavares and Vine (1985) reported that 
certain phthalates could interfere with forma-
tion of products from the COX and lipoxyge-
nase enzymes in rat peritoneal leucocytes. In 
the present study we focused exclusively on 
the PG pathway and therefore did not deter-
mine whether lipoxygenases are also inhibited. 
Fujimoto et al. (2005) meas ured PG inhibition 
in rabbit kidney medulla microsomes and con-
cluded that nonyl phenol directly inhibits COX 
activity. However, they also found that BPA 
and DBP did not have an inhibitory effect 
on the PG cascade, which is in conflict with 
our results and results from a study of perito-
neal leukocytes (Tavares and Vine 1985). We 
cannot explain this discrepancy, but it may 
be related to the use of different experimental 
designs; also, the proposed binding of EDCs to 
the COX enzymes should be confirmed using 
alternative experimental methods.
Genistein and other isoflavones have 
been reported to decrease PG synthesis in a 
neck cancer cell line (Ye et al. 2004), in pros-
tate cancer cells (Swami et al. 2007, 2009), 
and in prostate cancer patients (Swami 
et al. 2009), where the compounds report-
edly blocked the development and progres-
sion of prostate cancer. In a recent study 
Swami et al. (2009) reported that genistein 
decreased expression of COX enzymes with-
out affecting COX promoter activity. The 
authors argued that genistein most likely 
inhibits PG synthesis through repression 
of transcriptional activation by growth fac-
tors (Swami et al. 2009). However, Ye et al. 
(2004) reported that genistein inhibited the 
PG pathway without affecting COX gene 
expression, consistent with our data suggest-
ing that inhibition results from direct effects 
on COX enzyme activity. Interestingly, 
genistein has previously been reported to 
have dual effects in rats (Eustache et al. 
2009). Low doses of genistein (1 mg/kg/day) 
and vinclozolin (1 mg/kg/day) were more 
anti androgenic when added simultane-
ously than when added one at the time, but 
at higher doses (10 mg/kg/day genistein and 
30 mg/kg/day vinclozolin) the anti androgenic 
effect of vinclozolin was attenuated by 
genistein (Eustache et al. 2009). Although 
speculative, it is possible that the low-dose 
effect could be due to an anti androgenic effect 
by inhibition of PG synthesis.
Finally, if PG inhibition is involved in the 
mode of action of some EDCs, it raises the 
worrying possibility that pharmaceutical PG 
inhibitors such as ASA, Ace, and Ibu may act 
as endocrine disruptors. In our investigation 
of this we found that Ace indeed reduced the 
anogenital distance in rat pups after prenatal 
exposure and that prenatal exposure to ASA 
reduced testosterone production in fetal testis 
(Kristensen et al. 2010). Accordingly, in a 
prospective birth cohort study we found that 
use of ASA, Ace, and Ibu was associated with 
cryptorchidism in newborn boys (Kristensen 
et al. 2010), the best-known risk factor for 
reduced fertility and testicular germ cell 
cancers in adulthood (Boisen et al. 2004).
If inhibition of PG synthesis is the mecha-
nism of anti androgenicity of compounds such 
as phthalates, chronic inhibition of the PG 
pathway by a large number of EDCs com-
bined with several short-term high-dose expo-
sures to mild analgesics could have an impact 
on male reproductive health. Furthermore, 
a growing number of studies has shown that 
prenatal and early childhood exposure to Ace 
is associated with atopic diseases (Beasley et al. 
2008; Perzanowski et al. 2010; Rebordosa 
et al. 2008; Shaheen et al. 2002, 2005). Data 
in the present study show that some of the 
EDCs are more potent inhibitors of human 
primary mast cell responses after activation 
than is Ace; thus, this may suggest a link 
between exposure to environmental pollutants 
and disturbances of the immune system.
To conclude, the present study shows an 
unrecognized point of endocrine disruption 
through inhibtion of PG synthesis. Therefore, 
more research is needed to investigate whether 
EDCs could play a role in the increase of 
immunological and reproductive diseases 
through inhibition of the PG pathway. 
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